Early fibrosis inhibits hepatocellular carcinoma mediated by free radical effects

Mitochondrion

Volumn 13, Issue 5, 2013, Pages 391-398

  Muhanna, Nidal ^a   Doron, Sarit ^a   Abu Tair, Lina ^a   Zayyad, Hiba ^a   Mahamid, Mahmud ^a,b   Amer, Johnny ^a   Safadi, Rifaat ^a,b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b Israel   (Israel)

Author keywords

Cirrhosis; Free radicals; Hep3B cells; Hepatic fibrosis; Homeostasis; Phagocytosis

Indexed keywords

ALPHA FETOPROTEIN; FREE RADICAL; GLUTATHIONE; LEPTIN; MALONALDEHYDE; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD LEVEL; CANCER CELL CULTURE; CELL CONTACT; CELL INTERACTION; COCULTURE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LIVER FIBROSIS; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN SECRETION; TUMOR VOLUME;

MUS;

CIRRHOSIS; FREE RADICALS; HEP3B CELLS; HEPATIC FIBROSIS; HOMEOSTASIS; PHAGOCYTOSIS;

ALPHA-FETOPROTEINS; ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE; COCULTURE TECHNIQUES; DISEASE MODELS, ANIMAL; FREE RADICALS; HEPATIC STELLATE CELLS; HEPATOCYTES; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MICE; MICE, NUDE; OXIDATIVE STRESS; PHAGOCYTOSIS;

EID: 84882835656     PISSN: 15677249     EISSN: 18728278     Source Type: Journal    
DOI: 10.1016/j.mito.2013.01.001     Document Type: Article

References (29)

1. Afdhal N.H., Nunes D. Evaluation of liver fibrosis: a concise review. Am. J. Gastroenterol. 2004, 99:1160-1174.
2. Amer J., Goldfarb A., Fibach E. Flow cytometric analysis of the oxidative status of normal and thalassemic red blood cells. Cytometry A 2004, 60(1):73-80.
3. Batler R., Brenner D.A. Liver fibrosis. J. Clin. Invest. 2005, 115:209-218.
4. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
5. Fattovich G., Stroffolini T., Zagni I., Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004, 127(5 Suppl. 1):S35-S50.
6. Friedman S.L. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008, 134:1655-1669.
7. Ginsburg I., Sadovnic M., Oron M., Kohen R. Novel chemiluminescence-inducing cocktails, part I: the role in light emission of combinations of luminal with SIN-1, selenite, albumin, glucose oxidase and Co2+. Inflammopharmacology 2004, 12:289-303.
8. Ginsburg I., Sadovnic M., Oron M., Kohen R. Novel chemiluminescence-inducing cocktails, part II: measurement of the anti-oxidant capacity of vitamins, thiols, body fluids, alcoholic beverages and edible oils. Inflammopharmacology 2004, 12:305-320.
9. Ginsburg I., Koren E., Horani A., Mahamid M., Doron S., Muhanna N., Amer J., Safadi R. Amelioration of hepatic fibrosis via Padma Hepaten is associated with altered natural killer T lymphocytes. Clin. Exp. Immunol. 2009, 157:155-164.
10. Green D.R., Evan G.I. A matter of life and death. Cancer Cell 2002, 1:19-30.
11. Kisseleva T., Brenner D.A. Hepatic stellate cells and the reversal of fibrosis. J. Gastroenterol. Hepatol. 2006, 21(Suppl. 3):S84-S87.
12. Liu L., Zhu X.D., Wang W.Q., Shen Y., Qin Y., Ren Z.G., Sun H.C., Tang Z.Y. Activation of beta-catenin by hypoxia in hepatocellular carcinoma contributes to enhanced metastatic potential and poor prognosis. Clin. Cancer Res. 2010, 16:2740-2750.
13. Lockwood D.S., Yeadon T.M., Clouston A.D., Crawford D.G., Fawcett J., Callaghan S.A., Gotley D.C. Tumor progression in hepatocellular carcinoma: relationship with tumor stroma and parenchymal disease. J. Gastroenterol. Hepatol. 2002, 18:666-672.
14. Lowe S.W., Cepero E., Evan G. Intrinsic tumour suppression. Nature 2004, 432:307-315.
15. Melhem A., Mohanna N., Bishara A., Alvarez C.E., Ilan Y., Bishara T., Horani A., Nassar M., Friedman S.L., Safadi R. Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. J. Hepatol. 2006, 45:60-71.
16. Muhanna N., Horani A., Safadi R. Lymphocyte-hepatic stellate cell proximity suggests a direct interaction. Clin. Exp. Immunol. 2007, 148:338-347.
17. Muhanna N., Doron S., Wald O., Horani A., Eid A., Pappo O., Friedman S.L., Safadi R. Activation of hepatic stellate cells after phagocytosis of lymphocytes: a novel pathway of fibrogenesis. Hepatology 2008, 48:963-977.
18. Nhieu J.T., Brocheriou I., Preaux A.M., Mallat A., Cherqui D., Zafrani E.S., Mavier P. Myofibroblasts and hepatocellular carcinoma: an in vivo and in vitro study. J. Hepatol. 1998, 29:120-128.
19. Parkin D.M., Bray F., Ferlay J., Pisani P. Estimating the world cancer burden: Globocan. Int. J. Cancer 2001, 94:153-156.
20. Riaz A., Memon K., Miller F.H., Nikolaidis P., Kulik L.M., Lewandowski R.J., Ryu K.R., Sato T.K., Gates L.V., Mulcahy F.M., Baker T., Wang E., Gupta R., Nayar R., Benson B.A., Abecassis M., Omary R., Salem R. Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. J. Hepatol. 2011, 54:695-704.
21. Safadi R., Ohta M., Alvarez C.E., Fiel I., Bansal M., Mehal W., Friedman S.L. Immune stimulation of hepatic fibrogenesis by CD8 lymphocytes and its attenuation by transgenic interleukin 10 from hepatocytes. Gastroenterology 2004, 127:870-882.
22. Taimr P., Higuchi H., Kocova E., Rippe R.A., Friedman S., Gores G.J. Activated human stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology 2003, 37:87-95.
23. Thorgeirsson S.S., Grisham J.W. Molecular pathogenesis of human hepatocellular carcinoma. Nat. Genet. 2002, 31:339-346.
24. Villanueva A., Hoshida Y., Toffanin S., Lachenmayer A., Alsinet C., Savic R., Cornella H., Llovet J.M. New strategies in hepatocellular carcinoma: genomic prognostic markers. J. Clin. Cancer Res. 2010, 16:4688-4694.
25. Vogel S., Piantedosi R., Frank J., Lalazar A., Rockey D.C., Friedman S.L., Blaner W.S. An immortalized rat liver stellate cell line (HSC-T6): a new cell model for the study of retinoid metabolism in vitro. J. Lipid Res. 2000, 41:882-893.
26. Water J.A., Bailey C., Love C., Thomas H.C. A study of the antigenicity and immunogenicity of a new hepatitis B vaccine using a panel of monoclonal antibodies. J. Med. Virol. 1998, 54:1-6.
27. Zeng W., Gouw A.S., van den Heuvel M.C., Molema Molema G., Poppema S., van der Jagt E.J., de Jong K.P. Hepatocellular carcinomas in cirrhotic and noncirrhotic human livers share angiogenic characteristics. Ann. Surg. Oncol. 2010, 17:1564-1571.
28. Zhan S.S., Jiang J.X., Wu J., Halsted C., Friedman S.L., Zern M.A., Torok N.J. Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo. Hepatology 2006, 43:435-443.
29. Zhao W., Zhang L., Yin Z., Su W., Ren G., Zhou C., You J., Fan J., Wang X. Activated hepatic stellate cells promote hepatocellular carcinoma development in immunocompetent mice. Int. J. Cancer 2011, (Jan 6).